Gordon, C. M., Leonard, M. B., & Zemel, B. S. (2014). 2013 pediatric position development conference: executive summary and reflections. Journal of Clinical Densitometry, 17, 219–224.

Article  PubMed  Google Scholar 

Bishop, N., Arundel, P., Clark, E., et al. (2014). Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. Journal of Clinical Densitometry, 17, 275–280.

Article  PubMed  Google Scholar 

Ott, S. M. (2018). Cortical or trabecular bone: what’s the difference? American Journal of Nephrology, 47, 373–375. https://doi.org/10.1159/000489672.[PubMed][CrossRef][GoogleScholar]

Article  PubMed  Google Scholar 

El-Gazzar, A., & Hogler, W. (2021). Mechanisms of bone fragility: from osteogenesis imperfecta to secondary osteoporosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22020625

Article  PubMed  PubMed Central  Google Scholar 

Ganesan, K., Jandu, J. S., & Roane, D. (2021). Secondary osteoporosis. StatPearls.

Google Scholar 

McDonald, M. M., Khoo, W. H., Ng, P. Y., Xiao, Y., Zamerli, J., Thatcher, P., Kyaw, W., et al. (2021). Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell, 184(1330–347), e1313. https://doi.org/10.1016/j.cell.2021.02.002

Article  CAS  Google Scholar 

Wang, K., Ren, Y., Lin, S., Jing, Y., Ma, C., Wang, J., Yuan, X. B., Han, X., Zhao, H., Wang, Z., Zheng, M., Xiao, Y., Chen, L., Olsen, B. R., & Feng, J. Q. (2021). Osteocytes but not osteoblasts directly build mineralized bone structures. International Journal of Biological Sciences, 17, 2430–2448. https://doi.org/10.7150/ijbs.61012

Article  PubMed  PubMed Central  Google Scholar 

Thompson, W. R., Rubin, C. T., & Rubin, J. (2012). Mechanical regulation of signaling pathways in bone. Gene, 503(2), 179–193. https://doi.org/10.1016/j.gene.2012.04.076

Article  CAS  PubMed  PubMed Central  Google Scholar 

Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993). Vertebral fracture assessment using a semiquantitative technique. Journal of Bone and Mineral Research, 8, 1137–1148.

Article  CAS  PubMed  Google Scholar 

Joseph, S., McCarrison, S., & Wong, S. (2016). C: Skeletal fragility in children with chronic disease. Hormone Research in Pædiatrics, 86, 71–82. https://doi.org/10.1159/000447583

Article  CAS  PubMed  Google Scholar 

Binkovitz, L. A., & Henwood, M. J. (2007). Pediatric DXA: technique and interpretation. Pediatric Radiology, 37, 21–31. https://doi.org/10.1007/s00247-006-0153-y

Article  PubMed  Google Scholar 

Hogler, W., & Ward, L. (2015). Osteoporosis in children with chronic disease. Endocrine Development, 28, 176–195.

Article  CAS  PubMed  Google Scholar 

Baroncelli, G. I., & Bertelloni, S. (2014). The use of bisphosphonates in pediatrics. Hormone Research in Pædiatrics, 82, 290–302.

Article  CAS  PubMed  Google Scholar 

Rauch, F., Munns, C. F., Land, C., Cheung, M., & Glorieux, F. H. (2009). Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. Journal of Bone and Mineral Research, 24(7), 1282–1289. https://doi.org/10.1359/jbmr.090213

Article  CAS  PubMed  Google Scholar 

Simm, P. J., et al. (2018). Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. Journal of Paediatrics and Child Health., 54(3), 223–233. https://doi.org/10.1111/jpc.13768

Article  PubMed  Google Scholar 

Munns, C. F., Rauch, F., Zeitlin, L., et al. (2004). Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. Journal of Bone and Mineral Research, 19, 1779–1786.

Article  CAS  PubMed  Google Scholar 

Tuchman, S., Thayu, M., Shults, J., Zemel, B. S., Burnham, J. M., & Leonard, M. B. (2008). Interpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease. Journal of Pediatrics, 153, 484–490.

Article  CAS  PubMed  Google Scholar 

Gordon, C. M., Leonard, M. B., & Zemel, B. S. (2014). 2013 Pediatric position development conference: executive summary and reflections. Journal of Clinical Densitometry, 17(2), 219–224.

Article  PubMed  Google Scholar 

Vuorimies, I., Mayranpaa, M. K., Valta, H., et al. (2017). Bisphosphonate treatment and the characteristics of femoral fractures in children with osteogenesis imperfecta. Journal of Clinical Endocrinology and Metabolism, 102, 1333–1339.

Article  PubMed  Google Scholar 

Trejo, P., Fassier, F., Glorieux, F. H., et al. (2017). Diaphyseal femur fractures in osteogenesis imperfecta: characteristics and relationship with bisphosphonate treatment. Journal of Bone and Mineral Research, 32, 1034–1039.

Article  CAS  PubMed  Google Scholar 

Loizidou, A., Andronikou, S., & Burren, C. P. (2017). Pamidronate “zebra lines”: a treatment timeline. Radiol Case Rep., 12(4), 850–853. https://doi.org/10.1016/j.radcr.2017.07.003.PMID:29484085;PMCID:PMC5823313

Article  PubMed  PubMed Central  Google Scholar 

Semler, O., Netzer, C., Hoyer-Kuhn, H., et al. (2012). First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. Journal of Musculoskeletal and Neuronal Interactions, 12, 183–188.

CAS  PubMed  Google Scholar 

Hoyer-Kuhn, H., Netzer, C., Koerber, F., et al. (2014). Two years’ experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet Journal of Rare Diseases, 9, 145.

Article  PubMed  PubMed Central  Google Scholar 

Hoyer-Kuhn, H., Franklin, J., Allo, G., et al. (2016). Safety and efficacy of denosumab in children with osteogenesis imperfecta—a first prospective trial. Journal of Musculoskeletal and Neuronal Interactions, 16, 24–32.

CAS  PubMed  PubMed Central  Google Scholar 

Kumaki, D., Nakamura, Y., Sakai, N., et al. (2018). Efficacy of denosumab for glucocorticoid-induced osteoporosis in an adolescent patient with Duchenne muscular dystrophy: a case report. JBJS Case Connect, 8, e22.

Article  PubMed  Google Scholar 

Hogler, W., Briody, J., Moore, B., et al. (2005). Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency. Bone, 37, 642–650.

Article  PubMed  Google Scholar 

Fabre, S., Funck-Brentano, T., & Cohen-Solal, M. (2020). Anti-sclerostin antibodies in osteoporosis and other bone diseases. Journal of Clinical Medicine, 9(11), 3439. https://doi.org/10.3390/jcm9113439

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song, I. W., Nagamani, S. C., Nguyen, D., Grafe, I., Sutton, V. R., Gannon, F. H., Munivez, E., Jiang, M. M., Tran, A., Wallace, M., Esposito, P., Musaad, S., Strudthoff, E., McGuire, S., Thornton, M., Shenava, V., Rosenfeld, S., Huang, S., Shypailo, R., … Lee, B. (2022). Targeting TGF-β for treatment of osteogenesis imperfecta. The Journal of Clinical Investigation, 132(7), e152571. https://doi.org/10.1172/JCI152571

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hogler, W., Scott, J., Bishop, N., et al. (2017). The effect of whole body vibration training on bone and muscle function in children with osteogenesis imperfecta. Journal of Clinical Endocrinology and Metabolism, 102, 2734–2743.

Article  PubMed  Google Scholar